PEGASUS-2NCT03831256
PErsonalized Genomics for Prenatal Abnormalities Screening USing Maternal Blood
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 13 versions: 12 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Dec 31, 2023 to Sep 30, 2024 Show 7 more changesShow less
- Study completion date changed from estimate of Jun 30, 2025 to Jun 30, 2026
- Eligibility criteria expanded, about 7 words
- Trial completed
- Secondary endpoints: details revised at 3 of 9 entries
- Site details revised at 1 of 6 sites
- Collaborators: details revised at 1 of 12 entries
- Publications: details revised at 2 of 2 entries
- Minor Study completion date: Dec 31, 2024 to Jun 30, 2025v12
- Minor Study completion date: Dec 31, 2023 to Dec 31, 2024v11
Notable Primary completion date: Mar 31, 2023 to Dec 31, 2023v10 Show 4 more changesShow less
- Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 7500 to confirmed 7849
- Study completion date: Mar 31, 2024 to Dec 31, 2023
- Site details revised at 6 of 6 sites
- Minor Primary completion date: Dec 31, 2022 to Mar 31, 2023
- Study completion date: Apr 30, 2023 to Mar 31, 2024
- Site details revised at 1 of 6 sites
Show 6 earlier versionsHide 6 earlier versions
- Notable Primary completion date: Dec 31, 2021 to Dec 31, 2022
- Study completion date: Apr 30, 2022 to Apr 30, 2023
- Minor Study sites revised (6)v6
- Minor Enrollment target: 10000 to 7500v5
Notable Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
- Start date changed from estimate of Sep 2019 to Jan 13, 2020
- Primary completion date: Sep 2021 to Dec 31, 2021
- Study completion date: Dec 2021 to Apr 30, 2022
- Site details revised at 6 of 6 sites
- Notable Start date: Apr 2019 to Sep 2019v3
- Minor Secondary endpoints revised (9)v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (9)
Show 4 moreShow less
Arms and interventions
For the standard-of-care arm (2nd tier NIPS) women will undergo Traditional integrated prenatal screening i.e. traditional biochemical (+/- NT) and those with a positive screen for T21 or T18 will be offered Second-tier Non-invasive prenatal screening (NIPS) (for T21, T18, T13) or Invasive prenatal testing for fetal aneuploidy. Ultrasound examination in first and second trimester will be done based on clinical care practice ordered by health care provider. Pregnant women with a positive NIPS test will be offered Invasive prenatal testing for fetal aneuploidy (fetal chromosome analysis).
For the intervention arm (1st tier NIPS) women will receive First-tier Non-invasive prenatal screening (NIPS) i.e. provide a blood sample between 10-13+5 weeks gestation with NIPS results within 7 - 10 days of sample collection. Ultrasound examination in first and second trimester will be done based on clinical care practice ordered by health care provider. In case of a failed NIPS test (expected to be between 2% and 4% of samples), a new blood sample will be drawn for NIPS retest as well as for a traditional SIPS(serum integrated prenatal screening) or QUAD(quadruple marker prenatal screening) screen (depending on gestational age). Pregnant women with a positive NIPS test will be offered Invasive prenatal testing for fetal aneuploidy (fetal chromosome analysis).
Diagnostic tests: Traditional integrated prenatal screening, Second-tier Non-invasive prenatal screening (NIPS), First-tier Non-invasive prenatal screening (NIPS), Invasive prenatal testing for fetal aneuploidy
Sites
6 sites in 1 country